Novartis AG
NVS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $51,722 | $46,660 | $43,461 | $43,974 |
| % Growth | 10.8% | 7.4% | -1.2% | – |
| Cost of Goods Sold | $12,827 | $12,472 | $11,582 | $11,735 |
| Gross Profit | $38,895 | $34,188 | $31,879 | $32,239 |
| % Margin | 75.2% | 73.3% | 73.4% | 73.3% |
| R&D Expenses | $10,022 | $11,371 | $9,172 | $8,641 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $12,566 | $12,517 | $12,193 | $12,827 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,763 | $531 | $2,568 | $715 |
| Operating Expenses | $24,351 | $24,419 | $23,933 | $22,183 |
| Operating Income | $14,544 | $9,769 | $7,946 | $10,056 |
| % Margin | 28.1% | 20.9% | 18.3% | 22.9% |
| Other Income/Exp. Net | -$904 | -$646 | -$769 | $14,474 |
| Pre-Tax Income | $13,640 | $9,123 | $7,177 | $24,530 |
| Tax Expense | $1,701 | $551 | $1,128 | $1,625 |
| Net Income | $11,941 | $14,850 | $6,955 | $24,021 |
| % Margin | 23.1% | 31.8% | 16% | 54.6% |
| EPS | 5.92 | 7.15 | 3.19 | 10.71 |
| % Growth | -17.2% | 124.1% | -70.2% | – |
| EPS Diluted | 5.87 | 7.1 | 3.17 | 10.63 |
| Weighted Avg Shares Out | 2,018 | 2,077 | 2,181 | 2,243 |
| Weighted Avg Shares Out Dil | 2,035 | 2,092 | 2,197 | 2,260 |
| Supplemental Information | – | – | – | – |
| Interest Income | $568 | $629 | $378 | $71 |
| Interest Expense | $1,036 | $876 | $835 | $905 |
| Depreciation & Amortization | $6,069 | $8,277 | $6,705 | $5,597 |
| EBITDA | $20,715 | $18,255 | $14,682 | $30,914 |
| % Margin | 40.1% | 39.1% | 33.8% | 70.3% |